Literature DB >> 19226530

The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes.

King-Teh Lee1, Yi-Wei Lu, Shen-Nien Wang, Hong-Yaw Chen, Shih-Chang Chuang, Wen-Tsan Chang, Hon-Yi Shi, Chen-Guo Ker, Herng-Chia Chiu.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most malignant cancers in the world. The effect of preoperative transarterial chemoembolization (TACE) for resectable HCC is still controversial and cost-associated treatments are unknown.
METHODS: We retrospectively compared clinical outcomes and resource utilization after liver resection between patients who underwent preoperative TACE (TACE-LR group, n = 114) and those who did not (LR group, n = 236).
RESULTS: The overall mortality rate was 27.54% for the LR group versus 39.47% for the TACE-LR group (P < 0.05). The overall recurrent rates were 29.36% for the LR group versus 35.90% for the TACE-LR group (P > 0.05). Multivariate Cox regression analysis showed that preoperative TACE was a significant risk factor (P = 0.002, HR = 1.995, 95% CI 1.297-3.069) for overall long-term survival for HCC. The TACE-LR group had longer mean lengths of stay and higher hospital charges, both at index hospitalization and at 6 months for follow-up.
CONCLUSION: Preoperative TACE is not only associated with higher medical utilizations, but it is also correlated with higher mortality rates over a 5-year period. The preoperative TACE does not benefit patients with resectable HCC. The golden standard or clinical guidelines should be developed to provide better clinical decisions and decision support for HCC patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19226530     DOI: 10.1002/jso.21248

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  23 in total

1.  Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1α pathway in patients with hepatocellular carcinoma.

Authors:  Weiguang Xu; Jung-Hee Kwon; Young Ho Moon; Young Bae Kim; Yun Suk Yu; Namgyu Lee; Kwan Yong Choi; Yun Soo Kim; Yong Keun Park; Bong Wan Kim; Hee Jung Wang
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-23       Impact factor: 4.553

2.  The Negative Effect of Preoperative Transcatheter Arterial Chemoembolization on Long-Term Outcomes for Resectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Authors:  Masataka Amisaki; Soichiro Honjo; Masaki Morimoto; Takehiko Hanaki; Yosuke Arai; Naruo Tokuyasu; Teruhisa Sakamoto; Yasufumi Ohuchi; Hiroaki Saito
Journal:  Yonago Acta Med       Date:  2016-12-26       Impact factor: 1.641

3.  Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis.

Authors:  Chao Li; Ming-Da Wang; Lun Lu; Han Wu; Jiong-Jie Yu; Wan-Guang Zhang; Timothy M Pawlik; Yao-Ming Zhang; Ya-Hao Zhou; Wei-Min Gu; Hong Wang; Ting-Hao Chen; Jun Han; Hao Xing; Zhen-Li Li; Wan Yee Lau; Meng-Chao Wu; Feng Shen; Tian Yang
Journal:  Hepatol Int       Date:  2019-09-05       Impact factor: 6.047

4.  The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma.

Authors:  Jun Kajihara; Yoshito Tomimaru; Hidetoshi Eguchi; Daisaku Yamada; Hiroshi Wada; Akira Tomokuni; Tadafumi Asaoka; Koichi Kawamoto; Shigeru Marubashi; Hiroaki Nagano; Koji Umeshita; Yuichiro Doki; Masaki Mori
Journal:  Dig Dis Sci       Date:  2016-01-02       Impact factor: 3.199

5.  Effects of pre-operative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: Implication of circulating cancer cells by detection of α-fetoprotein mRNA.

Authors:  Masahiro Murakami; Hiroaki Nagano; Shogo Kobayashi; Hiroshi Wada; Masato Nakamura; Shigeru Marubashi; Hidetoshi Eguchi; Yutaka Takeda; Masahiro Tanemura; Koji Umeshita; Yuichiro Doki; Masaki Mori
Journal:  Exp Ther Med       Date:  2010-05-01       Impact factor: 2.447

6.  Preoperative ultrasound features as prognostic factors for patients with hepatocellular carcinoma.

Authors:  Zhi-Yong Shen; Gan-Lin Xia; Bing Hu; Yang-Gui Xie; Ming-Feng Wu
Journal:  Radiol Med       Date:  2015-01-09       Impact factor: 3.469

7.  Preresection transarterial chemoembolization for hepatocellular carcinoma: an experience with 23 patients.

Authors:  Mahesh Goel; Vinay Gaikwad; Tejas Dharia; Suyash Kulkarni; Nitin Shetty; Shailesh V Shrikhande
Journal:  Indian J Gastroenterol       Date:  2014-07-19

8.  Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma.

Authors:  Ke-Cheng Xu; Li-Zhi Niu; Qiang Zhou; Yi-Ze Hu; De-Hong Guo; Zheng-Ping Liu; Bing Lan; Feng Mu; Ying-Fei Li; Jian-Sheng Zuo
Journal:  World J Gastroenterol       Date:  2009-08-07       Impact factor: 5.742

9.  Absence of Benefit of Transcatheter Arterial Chemoembolization (TACE) in Patients with Resectable Solitary Hepatocellular Carcinoma.

Authors:  Tae-Yong Ha; Shin Hwang; Young-Joo Lee; Ki-Hun Kim; Gi-Young Ko; Dong Ii Gwon; Chul-Soo Ahn; Deok-Bog Moon; Gi-Won Song; Dong-Hwan Jung; Han Chu Lee; Young-Suk Lim; Kang Mo Kim; Ju Hyun Shim; Jeong-Heon Choi; Sung-Gyu Lee
Journal:  World J Surg       Date:  2016-05       Impact factor: 3.352

10.  Mortality predicted accuracy for hepatocellular carcinoma patients with hepatic resection using artificial neural network.

Authors:  Herng-Chia Chiu; Te-Wei Ho; King-Teh Lee; Hong-Yaw Chen; Wen-Hsien Ho
Journal:  ScientificWorldJournal       Date:  2013-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.